Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadhara SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoof G, Wong K-K, Hammerman PS. Adaptive resistance to therapeutic PD-1: PD-L1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17;7:10501. - Stand Up To Cancer

Blog

Posted October 8, 2019

Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadhara SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoof G, Wong K-K, Hammerman PS. Adaptive resistance to therapeutic PD-1: PD-L1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17;7:10501.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.